Troy Rafferty Secures $10 Million Verdict in Pharmaceutical Fraud Case

In a case involving allegations of pharmaceutical fraud, Troy Rafferty secured a $10 million verdict against a major drug manufacturer that had engaged in fraudulent marketing practices. Rafferty represented a whistleblower who exposed the company’s efforts to promote one of its drugs for off-label uses, which had not been approved by the FDA and posed significant risks to patients.

The pharmaceutical company had allegedly incentivized doctors to prescribe the drug for conditions it was not approved to treat, resulting in widespread misuse and potentially harmful side effects. The whistleblower, a former employee of the company, came forward with internal documents that revealed the company’s deceptive marketing strategies, which prioritized profits over patient safety.

Rafferty presented strong evidence that the company had engaged in fraudulent behavior, including offering kickbacks to healthcare providers to encourage off-label prescriptions. The $10 million verdict was a resounding victory for the whistleblower and a significant step forward in holding pharmaceutical companies accountable for unethical business practices.